en.sedaily.com
Organoid Science Enters Clinical Trials for Crohn's Disease Treatment
This is the first reported organoid-based intestinal regenerative therapy entering clinical trials, which could offer a new approach for Crohn’s patients whose ulcers don’t heal with current treatments. Early-stage safety testing means any clinical benefit is still unproven.
Adults with Crohn’s disease (especially those with nonhealing colonic ulcers), clinicians treating IBD, and researchers interested in regenerative medicine and organoid therapies.
What To Know
Organoid Science received Phase 1 IND approval in Korea for ATORM-C, an autologous intestinal organoid therapy for Crohn's disease with colonic ulcers. The trial is designed to assess safety, tolerability, maximum tolerated dose, and a recommended Phase 2 dose in 9–18 patients with follow-up up to 24 weeks at Asan Medical Center.
ATORM-C uses patients' own tissue-derived stem cells grown as intestinal organoids and transplanted to ulcerated mucosa to promote regeneration by differentiating into intestinal epithelial cells. The company positions this as a next-generation regenerative approach aiming to heal ulcers that do not respond to current therapies.
The report is a news summary of regulatory approval and trial start; it does not provide trial results, efficacy data, or patient-level outcomes.
Phase 1 trials focus on safety and dosing; they are small and exploratory. The article reports regulatory approval and trial design but contains no clinical results. Follow-up studies will be needed to determine effectiveness and long-term safety.
The piece is a company- and Korea-focused news report; readers may want to consult clinical trial registries or academic publications for detailed protocols and outcomes.
